Early Energy Deficit in Huntington Disease: Identification of a Plasma Biomarker Traceable during Disease Progression by Mochel, Fanny et al.
Early Energy Deficit in Huntington Disease: Identification
of a Plasma Biomarker Traceable during Disease
Progression
Fanny Mochel
1, Perrine Charles
2, Franc ¸ois Seguin
3, Julie Barritault
3, Christiane Coussieu
4, Laurence Perin
5, Yves Le Bouc
5, Christiane Gervais
6,
Guislaine Carcelain
7, Anne Vassault
8, Josue ´ Feingold
2, Daniel Rabier
8, Alexandra Durr
1,2*
1INSERM, Ho ˆpital de la Salpe ˆtrie `re, UMR 679, Paris, France, 2Assistance Publique-Ho ˆpitaux de Paris, Ho ˆpital de la Salpe ˆtrie `re, De ´partement de
ge ´ne ´tique et cytoge ´ne ´tique, Paris, France, 3INSERM, Faculte ´ de me ´decine et de pharmacie and Ho ˆpital La Mile ˆtrie, Poitiers, France, 4Assistance
Publique-Ho ˆpitaux de Paris, Ho ˆpital de la Salpe ˆtrie `re, Laboratoire d’endocrinologie, Paris, France, 5Assistance Publique-Ho ˆpitaux de Paris, Ho ˆpital
d’enfants Armand Trousseau, Explorations fonctionnelles endocriniennes, Paris, France, 6Assistance Publique-Ho ˆpitaux de Paris, Ho ˆpital de la
Salpe ˆtrie `re, Service de die ´te ´tique, Paris, France, 7Assistance Publique-Ho ˆpitaux de Paris, Ho ˆpital de la Salpe ˆtrie `re, Laboratoire d’immunologie, Paris,
France, 8Assistance Publique-Ho ˆpitaux de Paris, Ho ˆpital Necker-Enfants malades, Laboratoire de biochimie me ´tabolique, Paris, France
Huntington disease (HD) is a fatal neurodegenerative disorder, with no effective treatment. The pathogenic mechanisms
underlying HD have not been elucidated, but weight loss, associated with chorea and cognitive decline, is a characteristic
feature of the disease that is accessible to investigation. We, therefore, performed a multiparametric study exploring body
weight and the mechanisms of its loss in 32 presymptomatic carriers and HD patients in the early stages of the disease,
compared to 21 controls. We combined this study with a multivariate statistical analysis of plasma components quantified by
proton nuclear magnetic resonance (
1H NMR) spectroscopy. We report evidence of an early hypermetabolic state in HD. Weight
loss was observed in the HD group even in presymptomatic carriers, although their caloric intake was higher than that of
controls. Inflammatory processes and primary hormonal dysfunction were excluded.
1H NMR spectroscopy on plasma did,
however, distinguish HD patients at different stages of the disease and presymptomatic carriers from controls. This distinction
was attributable to low levels of the branched chain amino acids (BCAA), valine, leucine and isoleucine. BCAA levels were
correlated with weight loss and, importantly, with disease progression and abnormal triplet repeat expansion size in the HD1
gene. Levels of IGF1, which is regulated by BCAA, were also significantly lower in the HD group. Therefore, early weight loss in
HD is associated with a systemic metabolic defect, and BCAA levels may be used as a biomarker, indicative of disease onset
and early progression. The decreased plasma levels of BCAA may correspond to a critical need for Krebs cycle energy
substrates in the brain that increased metabolism in the periphery is trying to provide.
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INTRODUCTION
Huntington disease (HD) is a neurodegenerative disease with
autosomal dominant inheritance. The causal mutation is an
abnormally expanded CAG trinucleotide repeat in the first exon of
the HD1 gene on chromosome 4p, encoding a polyglutamine
stretch in the huntingtin protein. Although transcriptional
modifications, excitotoxicity, protein aggregation and loss of
normal function of huntingtin, have been hypothesized to be
responsible for the symptoms in patients [1], HD remains
a devastating disorder with no effective treatment. Access to
predictive DNA testing provides an opportunity for early
therapeutic intervention in presymptomatic individuals.
Despite the ubiquitous expression of mutated huntingtin, only
the pathophysiology of brain-related symptoms, which are
relatively inaccessible to investigation, have received attention.
However, unlike other neurodegenerative disorders, affected
HD patients are known to lose weight [2], despite normal, or
even increased, food intake [3,4]. In a group of 361 HD patients,
lower body mass index (BMI) has also been shown not to
correlate with dystonia or with chorea [5]. The demonstration
that mechanisms underlying weight loss in HD are related to
disease onset would indicate that a more systemic, and possibly
treatable, defect may be implicated early in the pathophysiology
of HD.
Therefore, we conducted a thorough multiparametric in-
vestigation exploring the underl y i n gc a u s e so fw e i g h tl o s si n
a group of patients with no or little signs of the disease,
compared to controls. This included the use of a multivariate
statistical analysis of plasma components quantified by proton
nuclear magnetic resonance (
1H NMR) spectroscopy. We
observed a systemic metabolic defect involving branched chain
amino acids (BCAA) in HD, associated with early weight loss.
T h er o l eo fB C A Ai nm i t o c h o n d r i al intermediary metabolism
may indicate a systemic attempt at compensating for the early
energy deficit in HD. These results further support recent data
relating altered mitochondrial energy metabolism in HD with
defect in the regulation of transcription caused by mutated
huntingtin [6].
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HD patients, presymptomatic carriers and controls
We included 32 individuals with abnormal CAG repeats
expansions (.36) in the HD1 gene (19 women and 13 men,
mean age of 42611 years, ranging from 28 to 80) and 21 controls
(13 women and 8 men, mean age of 3769.5 years, ranging from
27 to 62). In the HD group, 3 subgroups were constituted on the
basis of their symptoms determined by the Unified Huntington
disease rating scale (UHDRS) score [7]. There were 15 pre-
symptomatic individuals who had previously applied for predictive
testing, carriers of the HD1 mutation but without any significant
motor or cognitive signs of HD, as defined by UHDRS#3
(UHDRS 0.761.2). Ten HD mutation carriers were very mildly
affected, with 4#UHDRS#25 (UHDRS 11.964.9), and were
designated as early HD patients. The remaining 7 HD patients
had moderate signs of the disease, with 26#UHDRS#70
(UHDRS 44.4614.1), and were designated as mild HD patients.
Since diagnostic and predictive testing in HD is highly
confidential, family members were not chosen as a control group,
which consisted of healthy volunteers unrelated to HD mutation
carriers. All participants were enrolled in a clinical protocol
promoted by the Assistance Publique des Ho ˆpitaux de Paris (CRC
05129), and approved by the local ethics committee. Informed
consent was obtained for all participants. Motor dysfunction was
evaluated with the UHDRS and a total functional capacity score,
TFC [8]. We used a simplified validated questionnaire – the
patient health questionnaire, PHQ-9 – to evaluate depression [9].
Treatment and smoking habits were recorded. A detailed medical
history was obtained for each participant, especially conditions
known to affect body weight, such as malabsorption, renal
insufficiency, endocrine dysfunction and inflammatory process
(auto-immunity, cancer).
Determination of weight balance and caloric intake
Height and weight were recorded the day of the clinical
examination. The body mass index (BMI) was obtained by
dividing weight (in kilograms) by height (in meters) squared.
Bioelectrical impedance (TanitaH) was measured to evaluate the
lean mass and fat mass of all participants. Since this was a cross-
sectional study, changes in body weight were not evaluated
prospectively. Instead, the kinetics of body weight was determined
by subtracting current weight from the weight recorded in medical
records of each participant 5 years before inclusion in the study.
To determine caloric intake accurately, both opened and
closed-ended questionnaires were used. The opened-ended
questionnaire consisted of a semi-quantitative recording of the
patients’ regular food and beverage consumption during the three
days preceding the consultation. The accuracy of this question-
naire was verified one month later with a closed-ended
questionnaire that was sent to the homes of all participants. A
series of diagrams was used, reflecting the amount of each class of
food and beverage consumed over a 24-hour period. The same
methodology was strictly applied to assess caloric intake in HD
patients, presymptomatic carriers and controls. In order to
interpret changes in body weight, major changes in eating habits
during the past 5 years were also recorded, especially diets
intended to gain or lose weight. Mean total calories, proteins, lipids
and sugar intake for both the HD and control groups were
calculated using an automated system (Diaeta softwareH).
Multiparametric evaluation of weight balance
A standardized protocol was designed to thoroughly evaluate all
possible causes of weight loss andt oa v o i db i a s e sr e l a t e dt of o o d
intake and circadian fluctuations. It included sequentially: (i)
a minimal 12-hour fast the night preceding the examination, (ii)
collection of blood and urine at the same time (9 am), (iii)
ingestion of a standardized meal (450 calories) over a period of
10 minutes, (iv) collection of a second blood sample to determine
ghrelin values 1 hour after eating. Samples were stored on ice for
immediate analyses or frozen at 280uC for further analyses.
Routine analyses of blood chemistry, including liver and kidney
function, were performed. Serum insulin growth factor type 1
(IGF1) concentrations were measured using a specific immunor-
adiometric assay (IGF1 RIACT, Cis-Bio International, Gif- sur-
Yvette, France). The three main axes involved in the regulation of
weight balance were explored: (i) inflammation, by measuring of
CRP, ESR, IL1b and IL6 by ELISA (Diaclone, Besanc ¸on,
France), (ii) endocrine function, by measuring (at 9 am), fasting
serum cortisol, insulin, tetraiodothyronine (T4L) and thyroid
stimulating hormone (TSH) levels, fasting and fed ghrelin (8089-K,
Linco Research, St Louis, USA) levels, and fasting leptin levels
(HL-81HK, Linco Research, Paris, France); (iii) intermediary
metabolism, by measuring plasma amino acids and acylcarnitines,
as well as urinary organic acids [10,11].
For comparison of means, ANOVA or non-parametric tests
were used as appropriate (SPSSH software).
1H NMR spectroscopy of plasma
Plasma samples were prepared for
1H NMR spectroscopy with
minimal handling as described [12].F o rs t a t i s t i c a la n a l y s e so ft h e
whole metabolic profile, spectra were data reduced in numerical
format by integrating spectral regions (buckets) every 0.02 ppm
(parts per million) and scaled to the total intensity of the spectrum
with Amix 3.6.8 software (Bruker Analytische Messtechnik,
Germany) from 0.8 to 8.6 ppm; the water peak area was excluded
from each spectrum (4.4 to 5.2 ppm). Accordingly, each bucket of
the NMR spectrum corresponded to a single X variable.
Metabonomic studies, e.g. partial least squares analysis (PLS), consist
in multivariate statistical analyses with as many components as
variables. PLS (Simca-PH 11.0 software, Umetrics, Sweden) best
describe the variation within the NMR spectra according to a priori
classification, corresponding to a Y variable, which was the UHDRS
score in our study. Therefore, the pair-wise PLS scores were plotted
to identify principal components, maximizing the covariance
between all X (NMR spectrum) and Y (UHDRS) variables. The
greatest dispersion of the spectral profiles is usually observed in the
two first components of the analyses. A contribution plot was then
analyzed in order to determine the respective weight of variables that
contributed most to the difference between groups.
RESULTS
Clinical characteristics of the HD cohort
The 3 groups defined according to UHDRS scores showed similar
ages at examination (Table 1). Abnormal CAG repeats in the mildly
affected group were slightly smaller than in the early group, but the
latter were older at examination (Table 1). Early affected HD
patients had low chorea subscores (4.863.7), and all mildly affected
patients were autonomous and were able to live on their own, as
shown by mean TFC scores above 10 (Table 1). Depression scores of
the HD group were higher than those of controls (7.366.6, n=32
versus 0.761.6, n=21, p,0.001). Smoking was also more prevalent
in the HD group (n=12/32 versus 1/21 in controls, p=0.006).
Evidence of an early hypermetabolic state in HD
Retrospective analysis of body weight during the 5 years
preceding the study showed a significant weight loss in the
Plasma Biomarker in Early HD
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remained significant when men (p=0.002) and women
(p=0.003) were analyzed separately (Table 2). Mean weight
loss in early (23.162 . 9 K g )a n dm i l dH Dp a t i e n t s
(25.067.1 Kg) was significantly greater than in presymptom-
atic carriers (22.663.9 Kg) (p,0.01). Caloric intake recorded
over the 3-day period and the 24-hour period was similar, so
that the value, an essential determinant of weight balance, was
considered to be reliable both in the HD group and in controls.
No changes in diet or in conditions affecting body weight were
recorded over the 5 years preceding the study either of these
groups. Although HD mutation carriers had a higher caloric
intake, their BMI was similar. In women, the BMI of the HD
group was lower than the average for the French population
(BMI=23, in ‘Enque ˆte de ´cennale sante ´’, INSEE 2006), which
was not reflected by the controls from our study (BMI=21.3).
Importantly, in HD men, BMI was significantly lower than in
controls, and total caloric intake was inversely correlated with
weight (p=0.029) and lean body mass (p=0.004), which clearly
indicated a hypermetabolic state. Moreover, in presymptomatic
carriers, daily caloric intake was higher than in controls
(219564 9 5C a l ,n = 1 5v e r s u s1 6 6 5 6305 Cal, n=21,
p,0.001), as well as protein intake (85624 g, n=15 versus
70614 g, n=21, p=0.025). We found no correlation between
depression scores and food intake or between smoking habits
and weight loss.
ERS, CRP, serum interleukins IL 1ß (0.9663.82 pg/ml versus
0.2860.77 pg/ml) and IL 6 (0.5462.50 pg/ml versus
0.3960.89 pg/ml), on the one hand, and serum fasting cortisol
(13.464.4 mg/100 ml versus 16.766.8 mg/100 ml), insulin
(5.562.2 mU/ml versus 6.063.6 mU/ml), T4L (14.762.2 pmol/l
versus 16.461.9 pmol/l) and TSH (1.9260.90 mUI/l versus
1.8060.65 mUI/l), on the other hand, were similar in the HD
group and controls. Therefore, common causes of hypercatabolic
state, i.e. inflammation and classical endocrine dysfunctions, were
excluded. There was no glycosuria, and fasting blood glucose levels
were in the normal range in the HD group (4.760.4 mmol/l).
Identification of a systemic metabolic defect by
plasma
1H NMR
PLS analyses distinguished HD individuals at different stages of
the disease as shown in Figure 1. The difference between
presymptomatic carriers and early HD is shown in Figure 1a.
Early and mildly affected patients could be distinguished
(Figure 1b), as could controls and presymptomatic carriers, despite
some overlap (Figure 1c).
Metabolic profiles of plasma from early affected HD patients
were then compared to those of presymptomatic carriers, those of
mildly affected HD patients to early HD patients. The spectral
region that contributed to differences among the HD groups
determined from PLS contribution plots is shown in Figure 2.
There was a significant (.2SD) decrease along with disease
progression in the plasma concentrations of a group of variables
from the buckets located between 0.85 to 1.0 ppm on the NMR
spectrum. These peaks correspond to the branched chain amino
acids (BCAA), valine, leucine and isoleucine. No other significant
differences among the groups were detected in the spectra even
though very small buckets (0.02 ppm) were analyzed.
Confirmation that plasma BCAA are low in HD
To confirm that BCAA are affected in HD, we also measured their
concentrations in plasma by ion exchange chromatography.
Valine, leucine and isoleucine levels were significantly lower in the
HD group compared to controls (209647 mmol/l versus
245644 mmol/l, p=0.009; 118624 mmol/l versus 144623 mmol/
l, p,0.001 and 56612 mmol/l versus 68615 mmol/l, p=0.002,
respectively). In addition, the levels of each BCAA were correlated
with the observed weight loss in the patients (p=0.007, 0.003 and
0.017), and, more importantly, negatively correlated with UHDRS
values (p=0.017, ,0.0001 and 0.003) in both men (p=0.035, 0.019
and 0.036) and women (p=0.007 for leucine and 0.01 for
isoleucine). The number of CAG repeats was also negatively
correlated with valine (p=0.015), leucine (p=0.018) and isoleucine
(p=0.020). Although the BMI values of women with HD were
similar to those of controls, they had significantly lower leucine
(109619 mmol/l versus 134622 mmol/l, p=0.002) and isoleucine
(53610 mmol/l versus 65616 mmol/l, p=0.014) levels (Figure 3).
Interestingly, the plasma levels of the three BCAA were significantly
lower in patients at an early stage of the disease compared to
presymptomatic carriers (188635 mmol/l versus 229650 mmol/,
p=0.042, 105621 mmol/l versus 130624 mmol/l, p=0.019
and 4969 mmol/l versus 62612 mmol/l, p=0.024). The
plasma levels of valine (228650 mmol/l versus 245644 mmol/
l), leucine (130624 mmol/l versus 144623 mmol/l) and iso-
leucine (62612 mmol/l versus 68615 mmol/l) tended to be
lower in presymptomatic carriers than controls, although the
Table 1. Clinical characteristics of Huntington disease cohort.
..................................................................................................................................................
Presymptomatic Early HD Mild HD p
UHDRS=0.761.2 (0–3) UHDRS=11.964.9 (7–21) UHDRS=44.4614.1 (30–64)
n=15 n=10 n=7
CAG repeat expansion: (Number of repeats) 4262.0 (39–46) 45.864.7 (41–58) 44.462.0 (42–48) 0.017
Mean age at examination: (Years) 41.4612.9 (28–80) 38.269.3 (28–53) 49.366.0 (43–60) 0.057
Depression score: (30 maximal, worst) 4.464.5 (0–16) 10.468.5 (0–25) 9.365.5 (3–18) ,0.001
UHDRS, Chorea subscore* 0.260.6 (0–2) 4.863.7 (0–12) 16.965.8 (11–26)
UHDRS, Dystonia subscore* 0 0 2.662.6 (0–7)
Total functional score: (13 maximal, best) 1360 (13) 12.160.9 (11–13) 10.362.2 (8–13) ,0.001
*Chorea subscore 28 maximal, worst, dystonia subscore 20 maximal, worst
The values represent the mean6standard deviations. Ranges are in parentheses. Comparisons of means (ANOVA) were made among the 3 HD groups. UHDRS =
Unified Huntington disease rating scale, 120 is the maximal score of severity, up to 4 is considered as normal. The HD group included 15 strictly presymptomatic carriers,
10 patients at an early stage of the disease and 7 mildly affected patients. Ages at examination did not differ significantly among groups; presymptomatic HD carriers
were not younger than affected patients. Total functional score was close to maximal in all groups, even in mildly affected patients, in whom the mean TFC was greater
than 10. However, the depression score was pathological, even in presymptomatic carriers, and worsened with disease progression.
doi:10.1371/journal.pone.0000647.t001
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BCAA levels and age or smoking habits.
All other metabolic markers were similar in the HD group and
in controls. However, IGF1 levels were significantly lower in the
HD group than in controls (175648 ng/ml versus 210647 ng/
ml, p=0.011) and negatively correlated with UHDRS scores
(p=0.004). IGF1 levels were also correlated with leucine (p=0.04)
and isoleucine (p=0.02) levels. There was no correlation between
IGF1 levels and parameters associated with weight (BMI, lean and
fat body mass) or caloric intake.
In men, fasting and postprandial ghrelin levels were higher in
the HD group than in controls (17976719 pg/ml versus
10776453 pg/ml, p=0.024 and 13656538 pg/ml versus
8606291 pg/ml, p=0.021 respectively). However, women with
HD and controls had similar BMI values. Accordingly, ghrelin
levels were negatively correlated with BMI (p=0.008) but not with
the UHDRS score. Fasting ghrelin also correlated with caloric
intake in men (p=0.029), consonant with its orexigenic activity.
Importantly, the ratio between pre- and post-prandial ghrelin
levels were strictly identical in the HD group compared to controls
(1.35 versus 1.36) indicating that the negative feedback on
hypothalamus induced by food intake is functional in HD. Leptin
levels, which vary independently but inversely to ghrelin, were
lower in men with HD compared to controls (4.463.3 ng/ml
versus 12.4611.5 ng/ml, p=0.028), but not in women, and were
correlated with weight (p,0.001) and fat body mass (p,0.001),
but not with the UHDRS score.
DISCUSSION
This study is the first comprehensive investigation of the
physiopathology of weight loss in HD. We retrospectively
confirmed that weight loss begins early in the disease [5], despite
higher caloric intake, and is evident even in presymptomatic
mutation carriers and those with mild chorea, ruling out the role of
hyperactivity. This hypermetabolic state is not explained by
common mechanisms like inflammation or altered endocrine
functions, both of which have been incriminated in the
pathophysiology of HD [13,14]. High ghrelin levels and low
leptin levels in men with HD were reflective of their low BMI
compared to controls, and did not evolve with the disease. Thus
the ability of the hypothalamus to inhibit ghrelin synthesis after
food intake is functional in HD, contrary to a previous report [15].
Therefore, the hypermetabolic state of HD patients seems to be
part of the pathological process induced by mutated huntingtin.
Our
1H NMR spectroscopic analyses showed that a systemic
metabolic defect is associated with the status of HD carriers, as
well as disease progression. A selective decrease in branched chain
amino acids plasma concentrations distinguished presymptomatic
carriers from patients at an early stage of the disease and patients
at an early stage from mildly affected patients. Decreased plasma
BCAA levels were previously documented in more severely
affected HD patients, but the authors did not evaluate the
patients’ diet or weight [16,17]. Recently, a decrease of plasma
BCAA was found by mass spectrometry in HD patients at different
stages of the disease, in association with various metabolic changes
[18]. Our metabolic screening was sufficiently detailed to
demonstrate that plasma BCAA are the only metabolites that
differ between the HD patients and controls. A significant
difference between patients at an early stage of the disease and
presymptomatic carriers, was also observed regardless of sex. The
difference between presymptomatic carriers and controls, did not
reach statistical significance, however, consistent with the partial
Table 2. Nutritional characteristics of patients with Huntington disease according to sex, compared to controls.
..................................................................................................................................................
Total Men Women
HD (n=32) Controls (n=21) p HD (n=13) Controls (n=8) p HD (n=19) Controls (n=13) p
Weight loss (Kg)
A 23.364.5
(213 to 6)
2.863.9
(23t o1 0 )
,0.001 22.864.6
(213 to 2)
5.264.1
(0–10)
0.002 23.664.6
(212 to 6)
1.563.3
(23t o1 0 )
0.003
Present weight (kg) 64.4610.0
(48–89)
70.1617.7
(49–112)
0.140 71.0567.6
(61–88)
87.9615.4
(66–112)
0.003 59.8569.0
(48–78)
59.266.8
(49–68)
0.826
Height (cm) 168.768.1
(151–185)
170.366.6
(160–183)
0.442 175.765.7
(165–185)
176.264.7
(171–183)
0.845 163.865.6
(151–177)
166.764.7
(160–175)
0.140
BMI (kg/cm
2) 22.663.0
(18–29)
24.065.0
(18–38)
0.217 23.0562.8
(18–29)
28.3565.3
(21–38)
0.008 22.363.1
(18–29)
21.362.1
(18–26)
0.313
Lean Mass (kg)
B 50.768.3
(39–68)
52.7611.5
(39–72)
0.466 58.964.6
(53–68)
66.264.9
(57–72)
0.003 44.463.4
(39–51)
44.463.1
(39–48)
0.996
Fat Mass (kg)
B 20.96.8
(11–37)
24.266.4
(13–38)
0.124 12.264.8
(7–25)
21.65611.6
(9–43)
0.017 14.967.2
(6–29)
14.864.5
(9–22)
0.989
Calories (/24 h)
C 20206530
(985–3040)
16656305
(1280–2235)
0.008 22506376
(1720–2960)
17606355
(1280–2235)
0.017 18906565
(983–3041)
16106265
(1330–2130)
0.103
Proteins (gr/24 h)
C 81.3623.7
(42–121)
70.0614.1
(50–102)
0.054 86.3623.3
(53–121)
78.6615.9
(62–102)
0.583 78.4624.1
(42–117)
64.6610.0
(50–86)
0.058
Lipids (gr/24 h)
C 86.5618.3
(53–120)
65.7618.0
(47–126)
,0.001 90.4615.1
(61–114)
68.9611.9
(50–90)
0.006 84.2619.9
(53–120)
62.4621.2
(47–126)
0.008
Sugar (gr/24 h)
C 216.0677.1
(76–375)
191.3648.6
(123–310)
0.201 257.5660.2
(186–375)
196.0668.4
(123–310)
0.071 192.0676.8
(76–372)
188.4634.4
(130–256)
0.846
The values represent the mean6standard deviations. Ranges are in parentheses. The HD group was compared to controls (ANOVA).
ADetermined retrospectively for a 5-year period.
BDetermined by bioelectric impedance.
CDetermined from a 3-day and a 24-hour questionnaire performed at a one-month interval. Weight loss was significant in the HD group, in both men and women.
Despite significantly higher calories intake, carriers of huntingin mutations did not have a higher BMI (body mass index). In men, BMI and lean body mass were lower in
the HD group despite higher food intake. These nutritional analyses demonstrate the existence of a hypermetabolic state in the early stages of HD.
doi:10.1371/journal.pone.0000647.t002
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PLoS ONE | www.plosone.org 4 July 2007 | Issue 7 | e647overlap between the metabolic profiles of plasma observed by
1H
NMR spectroscopy. This is most likely due to the heterogeneity of
the presymptomatic group in which the estimated time to disease
onset varies among individuals, so that the metabolic profiles of
some presymptomatic carriers can be similar to those of controls.
Interestingly, the decrease in the levels of BCAA correlated with
weight loss in HD patients. Most importantly, it varied with HD
itself, i.e. with the UHDRS scores of the patients and the number
of CAG repeats in their mutations. Therefore, plasma BCAA can
be considered as relevant biomarkers of the early stages of HD.
For more severely affected patients, further analyses should be
performed. It is of note that very few metabonomic studies have
led to the identification of biomarkers that can be used routinely
for the follow up of patients. This is due to common experimental
and analytical biases in humans that include dietary intake, time of
sample collection, sample conditioning and chemical shifts due to
changes in pH [19,20]. The rigorous control of these parameters
in our study likely explains the accuracy of our NMR findings.
The implication of BCAA in mitochondrial intermediary
metabolism, both in brain and peripheral tissues, further supports
an important role for energy deficit in HD. A reduction in ATP
production was shown in brain of HD mice, including pre-
symptomatic mice [21]. A significant reduction in ATP levels and
mitochondrial respiration was also evidenced in striatal cells of HD
mice, although the respiratory chain complexes were not impaired
[22]. In HD patients, there is strong evidence for hypometabolism
Figure 1. Partial least square (PLS) analyses of NMR spectra of plasma samples from HD patients with no or little signs of the disease and
controls. Three groups of presymptomatic, early and mildly affected HD patients were constituted on the basis of their UHDRS scores, as described in
the methods. The first and second components in the X space (NMR spectrum) are denoted PC[1] and PC[2] respectively. PLS score plots (PC[1]/PC[2])
of pair-wise compared groups show the greater variation within the NMR spectrum according to a priori classification with UHDRS. There is a clear
separation between presymptomatic and early HD patients (a), as well as between early and mildly affected HD patients (b). Despite some overlap,
presymptomatic mutation carriers can also be distinguished from controls (c).
doi:10.1371/journal.pone.0000647.g001
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the basal ganglia, even in presymptomatic mutation carriers
[23,24,25]. The underlying cause of this early energy deficit in HD
brain is currently unknown, but impaired glycolysis [26], citric
acid cycle [27] and/or oxidative phosphorylation [22] may be
involved. Recently, mutated huntingtin was shown to decrease the
expression of PGC-1a (peroxisome proliferators-activated receptor
gamma coactivator-1a) in the striatum of HD mice and patients,
through a CREB-dependent transcriptional inhibition [28]. PGC-
1a is a transcriptional coactivator that regulates key energetic
metabolic pathways, both in the brain and peripheral tissues [29].
The possible role of PGC-1a in HD was initially suspected from
the observation of selective striatal lesions in the PGC-1a knockout
mouse [30]. Down-regulation of PGC-1a in HD striatum was then
shown to affect mitochondrial energy metabolism, possibly by
impairing oxidative phosphorylation [28]. In addition, the
inhibition of succinate dehydrogenase, by 3-nitropropionic acid
or malonate, mimics HD neuropathology in mice [31], indicating
that a lack of substrates for the citric acid cycle and the respiratory
chain is implicated in the energy deficit in HD brain. Importantly,
mitochondrial oxidation of BCAA leads to the production of
acetyl-CoA and succinyl-CoA, two key intermediates of the citric
acid cycle. Insufficient caloric or protein intake was excluded in
our study, as well as impairment of the BCAA oxidation pathway
since organic acid levels in urine were normal. Therefore, the
decrease in plasma BCAA observed in the HD group probably
Figure 2. Differences in the relative concentrations of branched chain amino acids in plasma are responsible for the differences among the HD
groups. PLS-contribution plots allow comparison of plasma metabolic profiles in early affected HD patients and presymptomatic carriers. NMR
variables that have the greatest weight (w*1; scaled in units of standard deviation), therefore contributing most to the separation between HD
groups, are decreased concentrations (.2SD) of metabolites located between 0.85 and 1.0 ppm: valine, leucine and isoleucine. A similar contribution
plot was obtained when plasma metabolic profiles from mildly affected HD patients were compared to early HD patients (data not shown).
doi:10.1371/journal.pone.0000647.g002
Figure 3. The levels of branched chain amino acids are significantly different in HD patients and controls. The concentrations of valine, leucine
and isoleucine in plasma were determined by ion exchange chromatography. Comparisons of means (ANOVA) were made between men or women
with HD and their respective controls. In men, there was a significant decrease of valine, leucine and isoleucine in the HD group. In women, similar
results are observed for leucine and isoleucine.
doi:10.1371/journal.pone.0000647.g003
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provide energy substrates to the citric acid cycle, as described in
various cachexia-producing illnesses [32,33]. The correlation
between decreased BCAA levels and weight loss in our study
suggests that excessive mobilization and oxidation of BCAA to
produce energy in muscle is associated with weight loss and
reduced lean body mass. The observation of weight loss prior to
neurocognitive decline suggests that neurological symptoms are
exacerbated when substrates from the periphery become in-
sufficient to compensate for the energy deficit in the HD brain.
The normal rate of oxygen consumption recently observed after
striatal infusion of succinate [34] supports the idea that providing
energy through an increase in both systemic and cerebral citric
acid cycle intermediates may be a promising therapeutic approach
in HD.
BCAT (branched-chain aminotransferase) is the first enzyme
involved in BCAA catabolism and is preferentially expressed in
muscle. Since altered energy metabolism has been shown in
muscle of HD patients [35], it remains to be determined whether
the systemic decrease in plasma BCAA also reflects an adaptive
response to a peripheral energy deficit in HD [36], in addition to
the energy deficit in the brain. As the two key enzymes of BCAA
oxidation, BCAT and BCKDH (a-keto acid dehydrogenase), are
widely expressed in the brain [37], the decrease in BCAA levels
detected in the cerebrospinal fluid of HD patients [16] may
indicate that BCAA oxidation is also activated in the brain to
compensate for the local energy deficit. Indeed, BCAA play an
important role in brain metabolism, accounting for up to 20% of
whole-body BCAA metabolism [38]. Leucine, in particular, is
a nitrogen donor for the glutamate-glutamine shuttle, with
transamination of a-keto-isocaproate to leucine leading to the
conversion of glutamate into a-ketoglutarate [39]. Low levels of
BCAA in the brain are, therefore, likely to impair the buffering of
glutamate, in accordance with previous studies showing altered
glutamate-glutamine cycling in HD [40]. Recently, excessive
oxidation of BCAA was observed in a BCKDH kinase knockout
mouse, emphasizing the importance of BCAA in intermediary
metabolism, in both brain and peripheral organs [41]. Indeed, the
systemic decrease in BCAA levels was associated not only with
weight loss, but also with motor dysfunction in adult mice.
Finally, our study showed that low plasma BCAA levels are
associated with reduced IGF1 levels in the HD group despite
a higher protein and caloric intake than controls. The tight
connection between IGF1 and essential amino acids has been
repeatedly demonstrated [42,43,44]. Interestingly, huntingtin is
a substrate of the serine-threonine Akt pathway, which is activated
by IGF1 [45]. Reduced activation of the Akt pathway has been
shown to decrease phosphorylation of mutated huntingtin,
resulting in increased neuronal toxicity [46]. Low levels of IGF1
in HD patients might contribute to the alteration in Akt activation
observed in HD animal models and patients [47].
This study provides the first demonstration of a systemic
metabolic defect in HD, associated with early weight loss. Plasma
BCAA represent a promising and accessible biomarker that may
be useful for the detection of disease onset and for monitoring
therapeutic trials in patients at an early stage of the disease.
Decreased plasma BCAA levels in HD strongly suggest a critical
need in the brain for citric acid cycle substrates provided by
peripheral organ metabolism.
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